Received: from westeu12-emailsignatures-cloud.codetwo.com (13.93.42.39) by DU2PEPF00028D0A.mail.protection.outlook.com (10.167.242.170) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9913.8 via Frontend Transport; Wed, 13 May 2026 10:58:34 +0000 Received: from DU2PEPF00028D0A.eurprd03.prod.outlook.com (2603:10a6:10:130:cafe::a2) by DB8P191CA0012.outlook.office365.com (2603:10a6:10:130::22) with Microsoft SMTP Server (version=TLS1_3, cipher=TLS_AES_256_GCM_SHA384) id 15.20.9913.12 via Frontend Transport; Wed, 13 May 2026 10:58:35 +0000 Received: from DB3PR08CU002.outbound.protection.outlook.com (40.93.64.87) by westeu12-emailsignatures-cloud.codetwo.com with CodeTwo SMTP Server (TLS12) via SMTP; Wed, 13 May 2026 10:58:34 +0000 Received: from GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104]) by GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104%4]) with mapi id 15.20.9913.009; Wed, 13 May 2026 10:58:32 +0000 Received: from GV2PR02MB11921.eurprd02.prod.outlook.com (2603:10a6:150:351::5) by DB9PR02MB10350.eurprd02.prod.outlook.com (2603:10a6:10:306::5) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9891.15; Wed, 13 May 2026 10:58:32 +0000 Received: from AM7PR02MB6180.eurprd02.prod.outlook.com (2603:10a6:20b:1a1::9) by VI1PR02MB5024.eurprd02.prod.outlook.com with HTTPS; Wed, 13 May 2026 10:58:41 +0000 Received: from DB8P191CA0012.EURP191.PROD.OUTLOOK.COM (2603:10a6:10:130::22) by AM7PR02MB6180.eurprd02.prod.outlook.com (2603:10a6:20b:1a1::9) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9913.11; Wed, 13 May 2026 10:58:37 +0000 From: "Kommunikatsioon - RA" To: =?iso-8859-1?Q?K=E4rolin_Jenas_-_RA?= References: In-Reply-To: Subject: Ed: Kommentaaripalve Date: Wed, 13 May 2026 13:58:32 +0300 Message-ID: MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_00BF_01DCE632.1BA39190" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQGVaERIn37JrJgtMMgBG71wbsdjVANeWAdZAt2ZTXYBs8/0Lw== Authentication-Results: spf=pass (sender IP is 13.93.42.39) smtp.mailfrom=ravimiamet.ee; dkim=none (message not signed) header.d=none;dmarc=pass action=none header.from=ravimiamet.ee; X-MS-Has-Attach: X-MS-TNEF-Correlator: x-ms-traffictypediagnostic: GV2PR02MB11921:EE_|DB9PR02MB10350:EE_|DU2PEPF00028D0A:EE_|AM7PR02MB6180:EE_|VI1PR02MB5024:EE_ X-MS-Office365-Filtering-Correlation-Id: 1276bf31-ee9f-4cc9-8800-08deb0de9404 X-MS-Exchange-AtpMessageProperties: SA X-Microsoft-Antispam-Untrusted: BCL:0;ARA:13230040|31052699007|366016|39142699007|8096899003|55112099003|13003099007|18002099003|22082099003|56012099003|11063799003|41050700001; X-Microsoft-Antispam-Message-Info-Original: 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 X-Forefront-Antispam-Report-Untrusted: CIP:255.255.255.255;CTRY:;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:GV2PR02MB11921.eurprd02.prod.outlook.com;PTR:;CAT:NONE;SFS:(13230040)(31052699007)(366016)(39142699007)(8096899003)(55112099003)(13003099007)(18002099003)(22082099003)(56012099003)(11063799003)(41050700001);DIR:INT; X-Exchange-RoutingPolicyChecked: HIHfL+5M3GQgRcCad0e1Da9IPaHYInoMykSnAFxCUSnRc5KSrZ8kBbksyJbdsnuPdbbpNUQirJty0nXdExs0L05pbS3g7YDwuenLqt8k7jOAl6qltq5y0r/Z+8K7ZiOV+n7WWJmD8660EC2e+B5D1DfrC1XiHuOZBae6ksnVHqAOl8vRg3p/AKDrO1hZB9+lHpsFurosEMJnNXNeTg527cft54GrQ9tpNrlIsMhWtfMJdW9hbkLiHomu7AdKcO6vMRjL/swfVX/y4kJ5PJemom7+kb7qoRCHIrQFYO5CL73HEY9qLQum/Ul97rcieGDm4B6EIjetXbLOPjui1RwMeQ== X-MS-Exchange-Transport-CrossTenantHeadersStamped: AM7PR02MB6180 X-MS-Exchange-Transport-CrossTenantHeadersStamped: DB9PR02MB10350 X-OrganizationHeadersPreserved: DB9PR02MB10350.eurprd02.prod.outlook.com X-CodeTwo-MessageID: 11ea7ad9-f31b-4616-9d24-4f6b8b3ada5c.20260513105833@westeu12-emailsignatures-cloud.codetwo.com X-CodeTwoProcessed: true X-MS-Exchange-Organization-ExpirationStartTime: 13 May 2026 10:58:34.5742 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Network-Message-Id: 1276bf31-ee9f-4cc9-8800-08deb0de9404 X-EOPAttributedMessage: 0 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-Exchange-Organization-AuthAs: Internal X-MS-Exchange-Organization-AuthMechanism: 04 X-MS-Exchange-Organization-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-Organization-SCL: 1 X-CrossPremisesHeadersPromoted: DU2PEPF00028D0A.eurprd03.prod.outlook.com X-CrossPremisesHeadersFiltered: DU2PEPF00028D0A.eurprd03.prod.outlook.com X-MS-Exchange-Transport-CrossTenantHeadersStripped: DU2PEPF00028D0A.eurprd03.prod.outlook.com X-MS-PublicTrafficType: Email X-OriginatorOrg: m1wmgpm3xrpm87txzdfw82by7.smtp.codetwo.online X-MS-Office365-Filtering-Correlation-Id-Prvs: 2dce51c6-0ec3-44d5-1abb-08deb0de92b2 X-Microsoft-Antispam: BCL:0;ARA:13230040|39142699007|31052699007|82310400026|35042699022|366016|55112099003|13003099007|11063799003|8096899003|18002099003|22082099003|56012099003|41050700001; X-Forefront-Antispam-Report: CIP:13.93.42.39;CTRY:NL;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:westeu12-emailsignatures-cloud.codetwo.com;PTR:westeu12-emailsignatures-cloud.codetwo.com;CAT:NONE;SFS:(13230040)(39142699007)(31052699007)(82310400026)(35042699022)(366016)(55112099003)(13003099007)(11063799003)(8096899003)(18002099003)(22082099003)(56012099003)(41050700001);DIR:INT; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 13 May 2026 10:58:34.5383 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: 1276bf31-ee9f-4cc9-8800-08deb0de9404 X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-OriginalAttributedTenantConnectingIp: TenantId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;Ip=[13.93.42.39];Helo=[westeu12-emailsignatures-cloud.codetwo.com] X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-FromEntityHeader: HybridOnPrem X-MS-Exchange-Transport-EndToEndLatency: 00:00:06.4754859 X-MS-Exchange-Processed-By-BccFoldering: 15.20.9891.020 X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(425001)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: 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 Content-Language: et received-spf: Pass (protection.outlook.com: domain of ravimiamet.ee designates 13.93.42.39 as permitted sender) receiver=protection.outlook.com; client-ip=13.93.42.39; helo=westeu12-emailsignatures-cloud.codetwo.com; pr=C authentication-results-original: dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; x-ms-exchange-organization-originalclientipaddress: 45.156.32.16 x-ms-exchange-organization-originalserveripaddress: 10.167.242.170 acceptlanguage: et-EE, en-US msip_labels: MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Enabled=True;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SiteId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SetDate=2026-05-13T10:58:31.318Z;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Name=All Employees (unrestricted);MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_ContentBits=1;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Method=Standard; X-OlkEid: 000000004C30E2D3CD34B4428531CBEB8A7CAB89070034AD76187591974DBF6C4F76951C873A0100020000000000B04CDEF8D3227A448511457FBBCE9C870000000008C00000D8AA2E615C54CD48808AB4372842094B This is a multipart message in MIME format. ------=_NextPart_000_00BF_01DCE632.1BA39190 Content-Type: text/plain; charset="iso-8859-1" Content-Transfer-Encoding: 8bit Selles e-kirjas sisalduv teave (kaasa arvatud manused) on mõeldud ametialaseks kasutamiseks ning seda võivad kasutada vaid e-kirja adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt väljendatud loata edasi saata ega mis tahes viisil kolmandatele isikutele avaldada. Juhul, kui Te olete saanud käesoleva e-kirja eksituse tõttu, teavitage sellest koheselt saatjat ning kustutage e-kiri. This e-mail and any attachments transmitted may contain confidential and privileged information. If you are not the intended recipient, please notify the sender immediately by returning the e-mail and permanently deleting what you have received. Any dissemination or use of this information by a third person without permission is prohibited and may be illegal. _____ Saatja: Anu Pillesson > Saadetud: teisipäev, 12. mai 2026 09:59 Adressaat: Kommunikatsioon - RA > Teema: Kommentaaripalve Tere Pöördun ravimiameti poole seoses Novo Nordisk Estonia OÜ reklaamikampaaniaga. Foto välireklaamist manuses. Palun teil kommenteerida alljärgnevat hiljemalt 15. maiks kella 9ks: 1. Kas Novo Nordisk Estonia OÜ on kõnealuse minukaal.ee reklaamikampaania teie juures eelnevalt kooskõlastanud või teid sellest teavitanud? 2. Kas olete seda reklaami ise hinnanud või saanud selle kohta kaebusi? 3. Reklaamil ei mainita ühegi ravimi nime, kuid see suunab veebilehele, kus on loetletud erakliinikud, kus pakutakse retseptiravimite (semaglutiid või tirsepatiid) ravi. Kas selline kaudne ahel (reklaam -> veebileht -> KMI kalkulaator -> ravimit pakkuvate kliinikute lehed + ravimitootja logo) võib Ravimiameti hinnangul kujutada endast ravimiseaduse § 82 tähenduses kaudset viidet retseptiravimile ning olla seega käsitletav keelatud reklaamina? 4. Kas plaanite algatada järelevalvemenetluse Novo Nordisk Estonia OÜ suhtes? 5. Millised on ravimiameti praktilised võimalused piiripealsete kampaaniate järelevalveks? 6. Kas olete varem teinud Novo Nordisk Estoniale ettekirjutusi ravimireklaami osas? Palun juurde ka kõneisiku fotot. Lugupidavalt Anu Pillesson Bestmarketing.ee toimetaja anu@bestmarketing.ee 5804 6002 Äripäev AS ------=_NextPart_000_00BF_01DCE632.1BA39190 Content-Type: text/html; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable

Selles e-kirjas = sisalduv teave (kaasa arvatud manused) on m=F5eldud ametialaseks = kasutamiseks ning seda v=F5ivad kasutada vaid e-kirja adressaadid. = E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt v=E4ljendatud = loata edasi saata ega mis tahes viisil kolmandatele isikutele avaldada. = Juhul, kui Te olete saanud k=E4esoleva e-kirja eksituse t=F5ttu, = teavitage sellest koheselt saatjat ning kustutage e-kiri. 
This = e-mail and any attachments transmitted may contain confidential and = privileged information. If you are not the intended recipient, please = notify the sender immediately by returning the e-mail and = permanently deleting what you have received. Any dissemination or = use of this information by a third person without permission is = prohibited and may be illegal. 

 

Saatja: Anu Pillesson <anu@bestmarketing.ee>
S= aadetud: teisip=E4ev, 12. mai 2026 = 09:59
Adressaat: Kommunikatsioon - RA <press@ravimiamet.ee>
Tee= ma: Kommentaaripalve

 

Tere

 

P=F6=F6rdun ravimiameti poole seoses Novo = Nordisk Estonia O=DC reklaamikampaaniaga. Foto v=E4lireklaamist = manuses.

 

Palun teil kommenteerida allj=E4rgnevat = hiljemalt 15. maiks kella = 9ks:

  1. Kas Novo Nordisk Estonia O=DC on k=F5nealuse minukaal.ee reklaamikampaania=  teie juures eelnevalt koosk=F5lastanud v=F5i teid sellest = teavitanud?
  1. Kas olete seda reklaami ise hinnanud v=F5i saanud selle = kohta kaebusi?
  1. Reklaamil ei mainita =FChegi ravimi nime, kuid see suunab = veebilehele, kus on loetletud erakliinikud, kus pakutakse = retseptiravimite (semaglutiid v=F5i tirsepatiid) ravi. Kas selline = kaudne ahel (reklaam -> veebileht -> KMI kalkulaator -> ravimit = pakkuvate kliinikute lehed + ravimitootja logo) v=F5ib Ravimiameti = hinnangul kujutada endast ravimiseaduse =A7 82 t=E4henduses kaudset = viidet retseptiravimile ning olla seega k=E4sitletav keelatud = reklaamina?
  1. Kas plaanite algatada j=E4relevalvemenetluse Novo = Nordisk Estonia O=DC suhtes?
  1. Millised on ravimiameti praktilised v=F5imalused = piiripealsete kampaaniate = j=E4relevalveks?
  1. Kas olete varem teinud Novo Nordisk Estoniale ettekirjutusi = ravimireklaami osas?

 

Palun juurde ka k=F5neisiku = fotot.

 

Lugupidavalt

 

Anu = Pillesson

Bestmarketing.ee= toimetaja

anu@bestmarketing.ee

5804 6002

=C4rip=E4ev = AS

------=_NextPart_000_00BF_01DCE632.1BA39190--